|
Treatment stratification in B-cell PTLD after solid organ transplantation (SOT) by international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial. |
|
|
Research Funding - Atara Biotherapeutics (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Abbvie; Atara Biotherapeutics; Celgene; Janssen; Roche |
|
|
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Janssen-Cilag |
|
|
Consulting or Advisory Role - Acerta Pharma/AstraZeneca; Bayer/Vital; Celgene/Jazz; Gilead Sciences; Janssen-Cilag; Novartis; Roche; Sandoz-Novartis |
Speakers' Bureau - Bayer Health; Celgene; Gilead Sciences; Janssen-Cilag; Roche Pharma AG |
Research Funding - Celgene (Inst); Janssen-Cilag (Inst); Mundipharma (Inst); Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche Pharma AG |
Research Funding - Amgen (Inst); Roche Pharma AG (Inst) |
|
|
Travel, Accommodations, Expenses - Daiichi Sankyo; Lilly |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; MSD; Roche; Takeda |
Travel, Accommodations, Expenses - Celgene; Merck |
|
|
Honoraria - Novartis; Pfizer |
Consulting or Advisory Role - Janssen Oncology; Novartis; Pfizer; Stemline Therapeutics |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); BerGenBio (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Kite/Gilead; Novartis; Roche; Takeda |
Travel, Accommodations, Expenses - Janssen; Kite/Gilead; Takeda |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Atara Biotherapeutics (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Atara Biotherapeutics; Celgene; Janssen |